Brii Biosciences (2137.HK) has significantly expanded its commitment to combatting Hepatitis B Virus (HBV) infection through new license agreements with VBI Vaccines, Inc. (NASDAQ: VBIV). These agreements grant Brii Bio exclusive access to develop and commercialize the clinically differentiated 3-antigen adult HBV prophylactic vaccine, PreHevbri®, in Greater China and Asia Pacific countries.
Additionally, the exclusive worldwide license for BRII-179 (VBI-2601), has been extended, paving the way for significant progress towards an HBV functional cure. In exchange for these rights, VBI will receive upfront payments of $15 million, including a $3 million equity investment from Brii Bio, as well as a share of commercial and regulatory milestones, and royalties. This is an exciting development in driving greater access to antiviral treatments and HBV control in the region.
We are excited to grow our partnership with VBI and expand our HBV pipeline, demonstrating our dedication to public health and the fight against HBV. Our BRII-179 (VBI-2601) is undergoing Phase 2 trials in China, which has produced promising results in the effort to achieve a functional cure. Intending to improve upon cure rates enabled with PEG-IFN-α alone, the BRII-179 combined with BRII-835 (VIR-2218) can expand the populations eligible for the treatment.
Additionally, PreHevbri®, a 3-antigen HBV vaccine, which has shown 5 to 8x higher antibody titers than Engerix-B and no unexpected reactogenicity in its pivotal Phase 3 PROTECT and CONSTANT clinical studies, is approved for use in Asia and Europe. We look forward to unlocking substantial revenue potential in high HBV prevalence areas and offering a more durable curative approach as we improve and combine cure strategies.
About BRII-179 (VBI-2601)
BRII-179 (VBI-2601) is an exciting new immunotherapeutic candidate that may help achieve a functional cure for chronic HBV infection. This recombinant protein-based immunotherapy expresses Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to boost B-cell and T-cell immunity. Currently, BRII-179 (VBI-2601) is being tested in two Phase 2 clinical trials in combination with BRII-835 (VIR-2218) and PEG-IFN-α, with promising results. We look forward to seeing the results of these studies and what this powerful immunotherapy can unlock for the future of HBV treatment.
PreHevbrio® is an amazing 3-antigen hepatitis B vaccine approved for use not only in the United States, but also the European Union/European Economic Area, United Kingdom, Canada, and Israel. It is made of the three hepatitis B surface antigens – S, pre-S1, and pre-S2 – making it an unparalleled vaccine. Those in the US and Canada can find it under the brand name PreHevbrio®, whereas those in the EU/EEA/UK can find it as PreHevbri®, and those in Israel as Sci-B-Vac®.
About Hepatitis B
Hepatitis B viral infection (HBV) is one of the world’s most significant infectious disease threats with more than 290 million people infected globally.1 Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV each year.1 HBV is of exceptional concern in China, where 87 million people are infected.2
About Brii Bio
Brii Biosciences (2137.HK), a biotechnology company with a mission to revolutionize life-saving treatments, is on the cutting edge of remedying some of the world’s foremost health challenges. Working on altering the treatment of infectious and central nervous system illnesses, Brii Bio is leading development of a functional cure for hepatitis B and pioneering effective solutions for postpartum depression and major depressive disorder. With a seasoned executive team managing operations in major biotech hubs like the San Francisco Bay Area, Beijing, and Shanghai, Brii Bio is at the forefront leveraging science and technology to make groundbreaking advances in medicine.